查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1804388

牛皮癣治疗市场：2025-2030 年全球预测（按药物类型、给药途径、疾病类型、最终用户和分销管道）

Psoriasis Treatment Market by Drug Type, Route of Administration, Disease Type, End-User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计牛皮癣治疗市场在 2024 年将达到 195.4 亿美元，2025 年将达到 211.9 亿美元，到 2030 年将达到 322.6 亿美元，复合年增长率为 8.71%。

主要市场统计数据
基准年（2024年） 195.4亿美元
预计年份（2025年） 211.9亿美元
预测年份（2030年） 322.6亿美元
复合年增长率（%） 8.71%

在不断发展的治疗方案和影响患者疗效的监管动态的背景下理解牛皮癣治疗范例

随着不断发展的治疗平台和法律规范重塑全球患者护理，了解银屑病治疗的复杂性至关重要。干癣是一种慢性疾病，会导致严重的身体不适和社会心理负担，迫切需要更有效、更有针对性的治疗。为此，製药公司和生技创新者越来越关注有望提高疗效、改善安全性并实现个人化治疗方法治疗流程的治疗方法。

突破性生物製药、数位护理平台、以患者为中心的治疗方案和整体疗法如何重新定义银屑病治疗的连续性

针对特定免疫途径的生物製药开启了精准医疗的新时代，为此前饱受中度至重度疾病折磨的患者带来了福音。同时，数位化医疗平台透过远端医疗咨询、远端监测症状进展和追踪依从性，使患者能够更有效地参与治疗计划。以患者为中心的通讯协定整合了穿戴式感测器和行动应用程序，透过促进患者与医疗服务提供者之间的协作，有助于改善治疗效果。

评估2025年提案关税对银屑病治疗供应链、定价策略和病患可近性的深远影响

2025年提案对进口活性药物原料药及牛皮癣治疗药物成品征收关税，势必对全球供应链带来压力。製造商将面临核心生物製药製剂成本上涨的风险，这可能导致其对生产地点进行策略性重新评估。因此，一些公司可能会加快对国内製造或其他筹资策略的投资，以降低可能因关税而导致的成本上涨风险。

识别药物治疗方式、给药途径、疾病变体、治疗环境和分销管道中的患者和提供者细分，以推动治疗决策

透过多种细分视角，可以更好地理解银屑病治疗现状，这些视角可以揭示患者和医护人员的细微行为差异。就药物类型而言，全身性治疗包括生物製药和照光治疗，而外用药物包括Calcineurin抑制剂、皮质类固醇、类视色素和维生素D类似物。在生物製药中，IL-17抑制剂、IL-23抑制剂、T细胞抑制剂和TNF-α抑制剂等标靶类别具有差异化的作用机制和安全性。这种精细化细分使相关人员能够将未满足的免疫学需求与临床开发平臺相匹配。

探索美洲、中东和非洲以及亚太地区影响牛皮癣治疗可近性和创新的独特动态

区域动态在塑造全球市场干癣治疗的可及性和创新性方面发挥关键作用。在美洲，报销框架和公私伙伴关係正在推动先进生物製药的快速应用，这得益于强大的专科药房网络，该网络为患者提供了支持服务。同时，各州之间的监管协调努力正在缩短新疗法的上市时间。

分析影响牛皮癣市场的主要生物製药和专业公司的策略性倡议、研究伙伴关係和产品创新

领先的生物製药和专科公司正在部署各种策略性倡议，以保持在银屑病领域的竞争力。先锋生物技术公司正在推进下一代 IL-17 和 IL-23 抑制剂的后期临床试验，而全球製药公司则正在扩大其口服小分子产品组合，推出旨在调节细胞内信号通路的药物。同时，专科製造商正在投资改良的局部用药，透过创新的给药系统和增强的皮肤耐受性来提高患者的依从性。

利用创新药物开发、病患协作和弹性供应链策略来改善牛皮癣治疗效果

为了抓住新兴市场机会，产业领导者应优先考虑利用精准免疫学和新型标靶途径的创新药物开发。从数位依从性平台到远距咨询服务，儘早整合病人参与工具，将有助于提高临床试验入组率和长期治疗依从性。此外，透过双重筹资策略建立弹性供应链框架，可以降低潜在关税波动和全球市场波动带来的风险。

为提供可靠的牛皮癣治疗见解而采用的综合混合方法、数据源集成和分析框架的详细信息

本分析中提出的全面见解是基于严格的混合方法。主要研究包括对关键意见领袖、皮肤病学专家和供应链专业人士的深入访谈，以获取有关临床和业务挑战的第一手观点。次要研究整合了同行评审日誌、监管备案文件和专有行业资料库，以对市场趋势进行三角测量并检验假设驱动的研究。

影响牛皮癣治疗和护理未来的关键发现、新兴机会和战略重点的摘要

本执行摘要揭示了治疗方法、数位参与和市场区隔的变革性变化，这些变化正在重新定义干癣治疗。从提案关税的策略影响，到患者亚型和区域动态的细微差别，相关人员如今对塑造治疗格局的力量有了更清晰的认识。新的商业机会蕴藏在标靶生物製药创新、数据主导的病患援助平台和弹性供应链架构的交汇处。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 专注于透过基因和生物标记分析实现个人化医疗，以优化牛皮癣治疗效果
  • IL-17 和 IL-23 抑制剂生技药品在中度至重度干癣治疗通讯协定中的应用日益增多
  • 扩大数位健康平台与远距皮肤科的整合，实现远距干癣管理
  • 生物相似生技药品的出现将推动成本竞争，扩大患者获得牛皮癣治疗的机会
  • 开发针对蛋白酪氨酸激酶的口服小分子抑制剂作为注射剂的替代品
  • 推出以患者为中心的支援计划，使用行动应用程式来提高患者对慢性牛皮癣治疗的依从性
  • 局部奈米製剂在增强药物渗透和减少牛皮癣全身副作用的进展
  • 扩大生物製药与照光治疗结合的联合治疗方案，以提高难治性病例的疗效
  • 新型PDE4抑制剂已获得监管机构核准，用于治疗轻度至中度干癣，为非生物製剂治疗提供新的选择
  • 加强真实世界证据研究，评估牛皮癣治疗的长期安全性和成本效益

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章：2025年美国关税的累积影响

第八章 银屑病治疗市场（依药物类型）

  • 全身性治疗
    • 生物製药
      • IL-17抑制剂
      • IL-23抑制剂
      • T细胞抑制剂
      • TNF-α抑制剂
    • 口服药物
    • 照光治疗
  • 局部治疗
    • Calcineurin抑制剂
    • 皮质类固醇
    • 类视色素
    • 维生素 D 类似物

9. 牛皮癣治疗市场（依给药途径）

  • 注射
  • 口服
  • 局部的

第 10 章 银屑病治疗市场（依疾病类型）

  • 红皮病型干癣
  • 水滴状干癣
  • 反向型干癣
  • 斑块型干癣
  • 脓疱型干癣

第 11 章 银屑病治疗市场（依最终用户划分）

  • 门诊手术中心（ASC）
  • 居家照护环境
  • 医院
  • 专科诊所

第 12 章 银屑病治疗市场（按分销管道）

  • 离线
    • 医院药房
    • 零售药局
  • 在线的

13.美洲牛皮癣治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14.欧洲、中东和非洲牛皮癣治疗市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

15. 亚太地区牛皮癣治疗市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十六章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • AbbVie Inc.
    • Almirall, SA
    • Amgen Inc.
    • Bausch Health Companies Inc.
    • Biogen Inc.
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Celltrion, Inc.
    • Eli Lilly and Company
    • Fresenius Kabi AG
    • GlaxoSmithKline plc
    • Johnson & Johnson Services, Inc.
    • LEO Pharma A/S
    • Lupin Limited
    • Merck & Co., Inc.
    • Mitsubishi Tanabe Pharma Corporation
    • Novartis AG
    • Pfizer Inc.
    • Samsung Bioepis Co., Ltd.
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • UCB SA
    • Viatris Inc.

第十七章 研究人工智慧

第十八章 研究统计

第十九章 研究联络人

第二十章 研究报导

第21章 附录

Product Code: MRR-115D84408DE0

The Psoriasis Treatment Market was valued at USD 19.54 billion in 2024 and is projected to grow to USD 21.19 billion in 2025, with a CAGR of 8.71%, reaching USD 32.26 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 19.54 billion
Estimated Year [2025] USD 21.19 billion
Forecast Year [2030] USD 32.26 billion
CAGR (%) 8.71%

Understanding the Psoriasis Treatment Paradigm Amid Evolving Therapeutic Options and Regulatory Dynamics Shaping Patient Outcomes

Understanding the complexities of psoriasis treatment is essential as evolving therapeutic platforms and regulatory frameworks reshape patient care worldwide. Chronic in nature, psoriasis imposes substantial physical discomfort and psychosocial burdens, prompting an urgent need for more effective, targeted interventions. In response, pharmaceutical and biotechnology innovators have intensified their focus on next-generation modalities that promise enhanced efficacy, improved safety profiles, and personalized treatment algorithms.

Moreover, intricate reimbursement landscapes and heightened patient expectations are driving stakeholders to reassess traditional care paradigms. Health systems seek integrated approaches that balance clinical outcomes with cost containment, while patients demand modalities that align with their lifestyles and long-term wellness goals. Consequently, a nuanced understanding of current market dynamics lays the foundation for stakeholders to identify areas of unmet need, anticipate regulatory shifts, and craft strategies that deliver sustainable value in the psoriasis treatment continuum.

How Breakthrough Biologics, Digital Care Platforms, Patient-Centric Protocols, and Holistic Approaches Are Redefining the Psoriasis Care Continuum

Breakthrough biologics targeting specific immune pathways have ushered in a new era of precision therapy, offering relief for patients who previously struggled with moderate to severe disease. At the same time, digital care platforms are empowering individuals to engage with treatment plans more effectively through telemedicine consultations, remote monitoring of symptom progression, and adherence tracking. Patient-centric protocols, which integrate wearable sensors and mobile applications, contribute to improved outcomes by fostering collaboration between patients and providers.

Meanwhile, holistic approaches that consider comorbidities such as arthritis, cardiovascular conditions, and mental health are gaining traction, ensuring that treatment regimens address the multifaceted nature of the disease. Consequently, the convergence of targeted biologics, advanced digital tools, and comprehensive clinical frameworks is redefining the psoriasis care continuum, setting new standards for efficacy, convenience, and long-term disease management.

Assessing the Far-Reaching Effects of Proposed 2025 Tariff Structures on Psoriasis Therapies Supply Chains, Pricing Strategies, and Patient Access

In 2025, proposed tariffs on imported active pharmaceutical ingredients and finished psoriasis therapies are poised to exert pressure on global supply chains. Manufacturers may face increased costs for core biologic components, leading to strategic reevaluations of production footprints. Consequently, some organizations could accelerate investments in domestic manufacturing or alternative sourcing strategies to mitigate exposure to potential tariff-related cost increases.

Furthermore, pricing strategies will likely evolve as payers and providers negotiate contracts that reflect shifting cost structures. In parallel, patient access programs and co-pay assistance initiatives may expand to preserve adherence among individuals reliant on costly biologics. Therefore, understanding the cumulative implications of these tariff proposals is critical for companies aiming to safeguard supply continuity, optimize pricing models, and maintain equitable access for the psoriasis patient population.

Uncovering Distinct Patient and Provider Segments Across Drug Modalities, Administration Routes, Disease Variants, Care Settings, and Distribution Channels Driving Treatment Decisions

The psoriasis treatment landscape is best understood through multiple segmentation lenses that illuminate nuanced patient and provider behaviors. When examining drug type, systemic treatments encompass biologics, oral medications, and phototherapy, while topical applications include calcineurin inhibitors, corticosteroids, retinoids, and vitamin D analogues. Within biologics, targeted classes such as IL-17 inhibitors, IL-23 inhibitors, T-cell inhibitors, and TNF-alpha inhibitors offer differentiated mechanisms of action and safety profiles. This granularity enables stakeholders to align clinical development pipelines with unmet immunological needs.

Analysis of administration routes reveals critical trade-offs between injectable, oral, and topical therapies. Injectable formulations often deliver potent systemic control but have higher complexity in patient administration and monitoring. Orally administered agents confer ease of use but must address first-pass metabolism and potential drug-drug interactions. Topical therapies remain fundamental for localized disease management, demanding formulations that optimize skin penetration and minimize irritation.

Disease type segmentation further sharpens market understanding by distinguishing between erythrodermic psoriasis, guttate psoriasis, inverse psoriasis, plaque psoriasis, and pustular psoriasis. Each subtype presents unique clinical manifestations, necessitating tailored therapeutic approaches and clinical trial designs. Additionally, end-user environments ranging from ambulatory surgical centers and homecare settings to hospitals and specialty clinics dictate distinct service delivery models and reimbursement considerations. Finally, distribution channel insights differentiate between offline pathways-hospital pharmacies and retail pharmacies-and online platforms, shaping omnichannel strategies that maximize patient reach and supply chain efficiency.

Exploring Unique Dynamics in the Americas, Europe Middle East & Africa, and Asia-Pacific Regions Influencing Psoriasis Treatment Accessibility and Innovation

Regional dynamics play a pivotal role in shaping psoriasis treatment accessibility and innovation across global markets. In the Americas, reimbursement frameworks and private-public partnerships have fostered rapid adoption of advanced biologics, supported by robust specialty pharmacy networks that facilitate patient support services. Meanwhile regulatory harmonization efforts across states are reducing time to market for novel therapies.

In Europe, Middle East & Africa, market heterogeneity is pronounced, with Western European nations benefiting from streamlined approval pathways and patient registries, while emerging economies in the Middle East and Africa face challenges related to infrastructure, diagnostic capacity, and healthcare funding. However, public health initiatives and international collaborations are gradually expanding access to both systemic and topical treatments, laying the groundwork for future growth.

Within Asia-Pacific, dynamic innovation hubs are emerging alongside established markets. Japan and Australia continue to invest heavily in biologic research and development, whereas Southeast Asian countries are rapidly scaling generic and biosimilar production to enhance affordability. Across the region, digital health adoption is accelerating, enabling remote patient monitoring and education programs that bridge gaps in specialist care delivery.

Analyzing Strategic Initiatives, Research Partnerships, and Product Innovations from Leading Biotech and Specialty Firms Shaping the Psoriasis Market

Leading biopharmaceutical and specialty firms are deploying a variety of strategic initiatives to maintain competitive positioning within the psoriasis arena. Biotech pioneers are advancing next-generation IL-17 and IL-23 inhibitors through late-stage clinical trials, while global pharmaceutical companies are expanding their oral small molecule portfolios with agents designed to modulate intracellular signaling pathways. Concurrently, specialty manufacturers are investing in reformulated topical therapies that improve patient adherence through novel delivery systems and enhanced skin tolerability.

Research partnerships between industry leaders and academic centers are accelerating the translation of biomarker discoveries into therapeutic candidates, particularly in the area of personalized medicine. Meanwhile, collaborations with contract manufacturing organizations are enabling scalable biologics production, thereby reducing time to market and enhancing supply chain resilience. In addition, strategic acquisitions and licensing deals are broadening product pipelines, ensuring that companies can address the full spectrum of disease severity and subtype variations.

Leveraging Innovative Drug Development, Collaborative Patient Engagement, and Resilient Supply Chain Strategies to Enhance Psoriasis Care Outcomes

To capitalize on evolving market opportunities, industry leaders should prioritize innovative drug development that leverages precision immunology and novel target pathways. Early integration of patient engagement tools-ranging from digital adherence platforms to remote consultation services-will enhance clinical trial enrollment and long-term treatment adherence. Additionally, establishing resilient supply chain frameworks with dual sourcing strategies can mitigate risks associated with potential tariff fluctuations and global disruptions.

Furthermore, forging multi-stakeholder collaborations with payers, patient advocacy groups, and regulatory bodies can streamline approval processes and foster transparent pricing dialogues. Investing in real-world evidence generation will also provide a stronger evidentiary basis for demonstrating long-term value, ultimately facilitating formulary inclusion and reimbursement approval. By embedding these recommendations within core strategic plans, companies can achieve sustainable growth and deliver superior patient outcomes in the psoriasis treatment landscape.

Detailing the Comprehensive Mixed-Methods Approach, Data Sources Integration, and Analytical Frameworks Employed to Deliver Robust Psoriasis Treatment Insights

A rigorous mixed-methods approach underpins the comprehensive insights presented in this analysis. Primary research consisted of in-depth interviews with key opinion leaders, dermatology specialists, and supply chain experts to capture firsthand perspectives on clinical and operational challenges. Secondary research integrated peer-reviewed journals, regulatory filings, and proprietary industry databases to triangulate market trends and validate hypothesis-driven inquiries.

Quantitative data was subjected to statistical validation techniques, ensuring the reliability of segmentation and regional models. Qualitative insights were coded thematically to uncover emerging patterns in therapeutic adoption, patient behavior, and competitive dynamics. Finally, synthesis workshops with cross-functional teams refined the analytical frameworks and stress-tested strategic scenarios. This multi-layered methodology ensures that the findings are both robust and actionable for decision-makers across the psoriasis treatment ecosystem.

Summarizing Key Findings, Emerging Opportunities, and Strategic Imperatives That Will Shape the Future of Psoriasis Treatment and Care Delivery

This executive summary has illuminated transformative shifts in therapeutic modalities, digital engagement, and market segmentation that are redefining psoriasis care. From the strategic implications of proposed tariffs to the nuanced differentiation of patient subtypes and regional dynamics, stakeholders now have a consolidated view of the forces shaping the treatment landscape. Emerging opportunities lie at the intersection of targeted biologic innovation, data-driven patient support platforms, and resilient supply chain architectures.

In closing, strategic imperatives include prioritizing precision medicine approaches, deepening cross-sector collaborations, and continuously adapting to regulatory evolutions. By aligning scientific breakthroughs with patient-centric delivery models and robust commercial frameworks, organizations can secure competitive advantage and advance the standard of care for individuals living with psoriasis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Focus on personalized medicine through genetic and biomarker profiling to optimize psoriasis treatment outcomes
  • 5.2. Growing uptake of IL-17 and IL-23 inhibitor biologics in treatment protocols for moderate to severe psoriasis
  • 5.3. Increasing integration of digital health platforms and teledermatology for remote psoriasis management
  • 5.4. Emergence of biosimilar biologics driving cost competition and expanded patient access to psoriasis therapies
  • 5.5. Development of oral small molecule inhibitors targeting tyrosine kinases as alternative to injectable treatments
  • 5.6. Implementation of patient-centric support programs leveraging mobile apps to improve adherence in chronic psoriasis care
  • 5.7. Advancements in topical nanoformulations to enhance drug penetration and reduce systemic side effects in psoriasis
  • 5.8. Expansion of combination therapy regimens combining biologics with phototherapy for enhanced efficacy in refractory cases
  • 5.9. Regulatory approval of novel PDE4 inhibitors for mild to moderate psoriasis offering new non-biologic options
  • 5.10. Heightened emphasis on real world evidence studies to assess long-term safety and cost effectiveness of psoriasis drugs

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Psoriasis Treatment Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Systemic Treatments
    • 8.2.1. Biologics
      • 8.2.1.1. IL-17 Inhibitors
      • 8.2.1.2. IL-23 Inhibitors
      • 8.2.1.3. T-cell Inhibitors
      • 8.2.1.4. TNF-alpha Inhibitors
    • 8.2.2. Oral Medications
    • 8.2.3. Phototherapy
  • 8.3. Topical Treatments
    • 8.3.1. Calcineurin Inhibitors
    • 8.3.2. Corticosteroids
    • 8.3.3. Retinoids
    • 8.3.4. Vitamin D Analogues

9. Psoriasis Treatment Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Injectable
  • 9.3. Oral
  • 9.4. Topical

10. Psoriasis Treatment Market, by Disease Type

  • 10.1. Introduction
  • 10.2. Erythrodermic Psoriasis
  • 10.3. Guttate Psoriasis
  • 10.4. Inverse Psoriasis
  • 10.5. Plaque Psoriasis
  • 10.6. Pustular Psoriasis

11. Psoriasis Treatment Market, by End-User

  • 11.1. Introduction
  • 11.2. Ambulatory Surgical Centers (ASCs)
  • 11.3. Homecare Settings
  • 11.4. Hospitals
  • 11.5. Specialty Clinics

12. Psoriasis Treatment Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Offline
    • 12.2.1. Hospital Pharmacies
    • 12.2.2. Retail Pharmacies
  • 12.3. Online

13. Americas Psoriasis Treatment Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Psoriasis Treatment Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Psoriasis Treatment Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AbbVie Inc.
    • 16.3.2. Almirall, S.A.
    • 16.3.3. Amgen Inc.
    • 16.3.4. Bausch Health Companies Inc.
    • 16.3.5. Biogen Inc.
    • 16.3.6. Boehringer Ingelheim GmbH
    • 16.3.7. Bristol-Myers Squibb Company
    • 16.3.8. Celltrion, Inc.
    • 16.3.9. Eli Lilly and Company
    • 16.3.10. Fresenius Kabi AG
    • 16.3.11. GlaxoSmithKline plc
    • 16.3.12. Johnson & Johnson Services, Inc.
    • 16.3.13. LEO Pharma A/S
    • 16.3.14. Lupin Limited
    • 16.3.15. Merck & Co., Inc.
    • 16.3.16. Mitsubishi Tanabe Pharma Corporation
    • 16.3.17. Novartis AG
    • 16.3.18. Pfizer Inc.
    • 16.3.19. Samsung Bioepis Co., Ltd.
    • 16.3.20. Sanofi S.A.
    • 16.3.21. Sun Pharmaceutical Industries Ltd.
    • 16.3.22. Takeda Pharmaceutical Company Limited
    • 16.3.23. UCB S.A.
    • 16.3.24. Viatris Inc.

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. PSORIASIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL PSORIASIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. PSORIASIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. PSORIASIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. PSORIASIS TREATMENT MARKET: RESEARCHAI
  • FIGURE 26. PSORIASIS TREATMENT MARKET: RESEARCHSTATISTICS
  • FIGURE 27. PSORIASIS TREATMENT MARKET: RESEARCHCONTACTS
  • FIGURE 28. PSORIASIS TREATMENT MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. PSORIASIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PSORIASIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PSORIASIS TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY IL-23 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY IL-23 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY T-CELL INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY T-CELL INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TNF-ALPHA INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TNF-ALPHA INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY PHOTOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY PHOTOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY RETINOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY RETINOIDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY VITAMIN D ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY VITAMIN D ANALOGUES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY GUTTATE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY GUTTATE PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY INVERSE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY INVERSE PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY PUSTULAR PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY PUSTULAR PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS (ASCS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS (ASCS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PSORIASIS TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 86. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 91. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 93. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 105. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 107. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 108. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 109. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 110. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 111. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 112. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 113. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 114. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 115. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 118. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 119. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 120. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES PSORIASIS TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 125. CANADA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. CANADA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 127. CANADA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 128. CANADA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 129. CANADA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 130. CANADA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 131. CANADA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 132. CANADA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 133. CANADA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 134. CANADA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 135. CANADA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. CANADA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 137. CANADA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 138. CANADA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 139. CANADA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 140. CANADA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 141. CANADA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 142. CANADA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 143. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 145. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 146. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 147. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 148. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 149. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 150. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 151. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 152. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 153. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 155. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 156. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 157. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 158. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 159. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 160. MEXICO PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 161. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 163. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 164. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 165. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 166. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 167. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 168. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 169. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 171. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 173. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 174. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 175. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 176. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 177. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 178. BRAZIL PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 179. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 181. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 182. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 183. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 184. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 185. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 186. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 187. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 188. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 189. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 192. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 193. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 195. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 196. ARGENTINA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 217. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 219. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 221. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 222. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 223. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 224. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 225. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 226. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 230. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED KINGDOM PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 235. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 237. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 238. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 239. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 240. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 241. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 242. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 243. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 245. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 247. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 248. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 249. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 251. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 252. GERMANY PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 253. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 255. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 256. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 257. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 258. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 259. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 260. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 261. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 263. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 265. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 266. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 267. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 269. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 270. FRANCE PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 271. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 273. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 274. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 275. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 276. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 277. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 278. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 279. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 281. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 283. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 284. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 285. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 287. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 288. RUSSIA PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 289. ITALY PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. ITALY PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 291. ITALY PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 292. ITALY PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 293. ITALY PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 294. ITALY PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 295. ITALY PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 296. ITALY PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 297. ITALY PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 298. ITALY PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 299. ITALY PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. ITALY PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 301. ITALY PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 302. ITALY PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 303. ITALY PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. ITALY PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 305. ITALY PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 306. ITALY PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 307. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 309. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 310. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 311. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 312. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 313. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 314. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 315. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 316. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 317. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 319. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 320. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 321. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 322. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 323. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 324. SPAIN PSORIASIS TREATMENT MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 325. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 327. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY SYSTEMIC TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 329. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 331. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
  • TABLE 333. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED ARAB EMIRATES PSORIASIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 335. UNI